Scancell Holdings Plc Change of Registered Office (4811C)

TIDMSCLP

RNS Number : 4811C

Scancell Holdings Plc

13 April 2017

13 April 2017

Scancell Holdings Plc

("Scancell" or the "Company")

Change of Registered Office

Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, announces that it has changed its registered office address.

The new registered office address for Scancell is:

John Eccles House

Robert Robinson Avenue

Oxford Science Park

Oxford OX4 4GP

For Further Information:

Scancell Holdings Plc

 
 Dr John Chiplin, Executive                         +1 858 900 
  Chairman                                           2646 
  Dr Richard Goodfellow,       Scancell Holdings     +44 (0) 20 
  CEO                           Plc                  3727 1000 
 
 Freddy Crossley (Corporate                         +44 (0) 20 
  Finance)                                           7886 2500 
  Tom Salvesen (Corporate      Panmure Gordon        +44 (0) 20 
  Broking)                      (UK) Limited         7886 2500 
 
                                                    +44 (0) 20 
 Mo Noonan/Simon Conway        FTI Consulting        3727 1000 
 

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody(R) and Moditope(R) technology platforms.

Scancell's first ImmunoBody(R), SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell's ImmunoBody(R) vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. Experimental data suggests that the high avidity T cells induced by ImmunoBody(R) vaccines increase expression of PDL-1 on the tumour cell surface, thereby making the tumours more sensitive to checkpoint inhibitor drugs. Re-challenging animals with tumour cells after SCIB1 treatment resulted in 100% survival suggesting that ImmunoBody(R) induces a powerful memory response. Such an effect has not been observed with checkpoint inhibitors.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope(R) platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CROIJMBTMBJBBPR

(END) Dow Jones Newswires

April 13, 2017 07:39 ET (11:39 GMT)